Innovative therapeutics


Press Releases

Press Releases
  Date Title View
Dec 12, 2016
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most common form of dwarfism. The first child enrolled in the s...
Nov 3, 2016
- Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona - Jefferies 2016 London Healthcare Conference on November 16 in London - Citi 2016 Global Healthcare Conference on December 8 in New York City ...
Oct 27, 2016
- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million - Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016 - Kuvan Net Product Revenues Increase 42% Year ...
Oct 19, 2016
Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose Consistent Safety Profile at High Dose Findings Support 15 µg/kg/day in Phase 3, Randomized Controlled Study to Start by End...
Oct 13, 2016
Phase 1/2 Study Expected to Resume by End of 2016 Requirement for Prophylactic Corticosteroids Removed SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in...
Oct 11, 2016
SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27, at 4:30 p.m. ET to discuss third quarter 2016 financial results and p...
Sep 21, 2016
BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008) Patent Trial and Appeal Board Ruled in BioMarin's Favor on Method of Use (MOU) Patent Interference (No. 106,013) SAN RAFAEL, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. ...
Sep 15, 2016
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Brineura™ (cerliponase alfa) to treat children with CLN2 disease, a form of Batten disease. Validation o...
Sep 8, 2016
SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company's products and product candidates will be made at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2016 Annual Meeting, which will be held on Septem...
Sep 6, 2016
Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017 Additional 8 Months of Treatment (81-Week Data) Show Maintenance of Efficacy, Consistent with Previously Submitted 48-Week Data SAN RAFAEL, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) ...
... NextLast
= add release to Briefcase


MPS I, MPS VI, PKU, LEMS, Lysosomal Storage Disorders, Morquio A/MPS IVA


VIMIZIM™, Kuvan®, Naglazyme®, Aldurazyme®, Firdapse®

Patient/Physician Contact Information

BioMarin Patient and Physician Support (BPPS)
Tel: 866.906.6100
Fax: 888.863.3361